Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31547036 | 0.81 | ALDH1A1 (0.46) | ALDH1A1NPSR1L3MBTL1TSHRKDM4E | |
| SCHEMBL2648204 | 0.81 | ALDH1A1 (0.46) | ALDH1A1NPSR1L3MBTL1TSHRKDM4E | |
| SCHEMBL1869642 | 0.79 | ALDH1A1 (0.49) | ALDH1A1NPSR1L3MBTL1TSHRKDM4E | |
| SCHEMBL1006462 | 0.79 | ALDH1A1 (0.49) | ALDH1A1NPSR1L3MBTL1TSHRKDM4E | |
| SCHEMBL31547005 | 0.79 | ALDH1A1 (0.49) | ALDH1A1NPSR1L3MBTL1TSHRKDM4E | |
| SCHEMBL7626922 | 0.79 | ALDH1A1 (0.49) | ALDH1A1NPSR1L3MBTL1TSHRKDM4E | |
| SCHEMBL7128100 | 0.78 | GABRA1 (0.35) | ALDH1A1 | |
| SCHEMBL4680121 | 0.77 | L3MBTL1 (0.46) | ALDH1A1NPSR1L3MBTL1TSHRCYP2D6 | |
| SCHEMBL234449 | 0.71 | ALDH1A1 (0.47) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1547695 | 0.71 | SHBG (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| US-6521656-B1 | Contacting sperm with a pyrazolo(1,5-a)pyridine acrosomal reaction induction promoter then joining with ovum | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-0823254-B1 | NOVEL USE OF PYRAZOLOPYRIDINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-17 | — | — | EP | disclosed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-0497258-B1 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6303624-B1 | PREVENTION AND/OR TREATMENT OF HYPERPHOSPHATEMIA OR SECONDARY HYPERPARATHYROIDISM, INCLUSIVE OF ACCESSORY DISORDERS BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHICH COMPRISES AN ADENOSINE ANTAGONIST COMPOUND OR ITS SALT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6214843-B1 | TREATING AND/OR PREVENTING GASTROINTESTINAL DYSFUNCTION WITH A PYRAZOLOPYRIDINE COMPOUND WHICH COMPRISES AN ADENOSINE ANTAGONIST COMPOUND OR ITS SALT | FUJITSAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| EP-1084710-A1 | REMEDIES FOR MALE STERILITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0972525-A1 | PREVENTIVES AND REMEDIES FOR HYPERPHOSPHATEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-01-19 | — | — | EP | disclosed |
| EP-0900796-A1 | PREVENTIVES AND REMEDIES FOR ISCHEMIC INTESTINAL LESION AND ILEUS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0823254-A1 | NOVEL USE OF PYRAZOLOPYRIDINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| EP-0644762-B1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-12-17 | — | — | EP | disclosed |
| US-5643938-A | RAISING THE ERYTHROPOIETIN LEVEL IN HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| EP-0644762-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-29 | — | — | EP | disclosed |
| US-5338743-A | Pancreatitis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-16 | — | — | US | disclosed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | ALDH1A1 336/4885NPSR1 68/4885L3MBTL1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.